RxDoctor Payments Data

Edward Oruci, MD

Interventional Cardiology · Roslyn, NYNPI 1619955499

Payments from drug & device makers

$15,906in general payments, 2019–2025

Across 715 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Amgen$2K
  • Novartis$2K
  • AstraZeneca$1K
  • Johnson & Johnson$836
  • Merck$831
  • plus $8K from 31 others

What the payments were for

  • Food & beverage$15,875100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,906 in reported general payments places this provider in the 55th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$639,514
Medicare patients
1,117
Services billed
5,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban301$302,358
Repatha SureclickEvolocumab329$237,934
XareltoRivaroxaban228$232,005
EntrestoSacubitril/Valsartan146$189,699
BrilintaTicagrelor69$56,719
MultaqDronedarone Hcl31$38,208
WegovySemaglutide18$28,157
Praluent PenAlirocumab48$23,720
FarxigaDapagliflozin Propanediol12$18,176
JardianceEmpagliflozin13$17,353
Rosuvastatin Calcium954$16,283
Repatha SyringeEvolocumab11$13,730
Metoprolol Succinate766$12,713
EdarbyclorAzilsartan Med/Chlorthalidone16$8,440
Dabigatran EtexilateDabigatran Etexilate Mesylate20$8,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$795$302,358301 claims
Johnson & JohnsonXarelto$836$232,005228 claims
NovartisEntresto$1,654$189,699146 claims
AstraZenecaBrilinta, Farxiga$1,196$74,89581 claims
Sanofi-aventis U.S. LLCMultaq$327$38,20831 claims
Novo NordiskWegovy$526$28,15718 claims
Boehringer IngelheimJardiance, Pradaxa$784$22,83724 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$240$8,44016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →